EGFR and non-small cell lung carcinoma: A combination of osimertinib and anti-HER2 agent trastuzumab emtansine was reported to overcome osimertinib resistance in T790M-positive EGFR-mutated NSCLC cell lines which gained HER2 amplification (24).